Te­va sees rev­enue in­creas­es in Q2 as it con­tin­ues its ‘piv­ot to growth’ dri­ve

Te­va is con­tin­u­ing its “piv­ot to growth” ini­tia­tive by mark­ing an in­crease in rev­enue for the sec­ond quar­ter.

The phar­ma re­vealed its Q2 re­sults on Wednes­day, pulling in rev­enues of $3.9 bil­lion that marked a 4% jump from the sec­ond quar­ter of last year. Te­va CEO Richard Fran­cis said on the in­vestor call that the high­er num­bers were led by the com­pa­ny’s “growth en­gines,” which in­clude the drugs Auste­do, Ajovy and its gener­ics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER